Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Selexipag
Drug ID BADD_D02006
Description Selexipag was approved by the United States FDA on December 22, 2015 for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization. PAH is a relatively rare disease with usually a poor prognosis requiring more treatment options to prolong long-term outcomes. Marketed by Actelion Pharmaceuticals under brand name Uptravi, selexipag and its active metabolite, ACT-333679 (MRE-269), act as agonists of the prostacyclin receptor to increase vasodilation in the pulmonary circulation and decrease elevated pressure in the blood vessels supplying blood to the lungs.
Indications and Usage Selexipag is indicated for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization.
Marketing Status Prescription
ATC Code B01AC27
DrugBank ID DB11362
KEGG ID D09994
MeSH ID C523468
PubChem ID 9913767
TTD Drug ID D0N2SR
NDC Product Code 66215-718; 70600-029; 66215-610; 66215-608; 66215-604; 66215-602; 66215-628; 66215-612; 66215-614; 70600-007; 66215-606; 46708-918; 66215-616
Synonyms selexipag | 2-(4-((5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)-N-(methylsulfonyl)acetamide | Uptravi | NS-304 | ACT 293987 | ACT293987 | ACT-293987
Chemical Information
Molecular Formula C26H32N4O4S
CAS Registry Number 475086-01-2
SMILES CC(C)N(CCCCOCC(=O)NS(=O)(=O)C)C1=CN=C(C(=N1)C2=CC=CC=C2)C3=CC=CC=C3
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Restless legs syndrome17.02.07.008; 15.05.03.0120.000742%Not Available
Hot flush21.02.02.001; 08.01.03.027; 24.03.01.0050.000556%
Cardiac disorder02.01.01.0030.000387%Not Available
Feeding disorder14.03.02.003; 19.09.01.0030.000927%Not Available
Limb discomfort15.03.04.0140.000371%Not Available
Lung infection22.07.01.008; 11.01.09.0080.000556%
Upper limb fracture15.08.03.018; 12.04.01.0180.000556%Not Available
Decreased appetite08.01.09.028; 14.03.01.0050.008347%
Lower limb fracture15.08.03.004; 12.04.01.0040.000556%Not Available
Respiratory syncytial virus infection22.07.02.002; 11.05.13.0010.000371%Not Available
Disease progression08.01.03.0380.001016%
Drug intolerance08.06.01.0130.003524%Not Available
Respiratory tract infection11.01.08.017; 22.07.07.0010.000742%Not Available
Unevaluable event08.01.03.0510.003895%Not Available
Poor quality sleep19.02.05.005; 17.15.04.0020.000371%Not Available
Pulmonary arterial hypertension22.06.01.002; 24.08.03.0030.001694%Not Available
Oropharyngeal pain22.02.05.022; 07.05.05.004--
Acute kidney injury20.01.03.016--
Immune thrombocytopenic purpura10.04.01.008; 01.08.01.0070.000371%Not Available
Anal incontinence17.05.01.021; 07.01.06.0290.000371%
Liver function test increased13.03.01.0440.000556%Not Available
Frustration tolerance decreased19.04.02.0160.000371%Not Available
Cardiac failure chronic02.05.01.0090.000097%Not Available
Catheterisation cardiac13.14.07.0030.000371%Not Available
Concomitant disease aggravated08.01.03.0630.000927%Not Available
Terminal state08.01.03.0790.000371%Not Available
Clostridium difficile infection11.02.02.0090.000927%Not Available
Oxygen consumption increased13.02.01.0270.002226%Not Available
Quality of life decreased13.18.01.0130.000371%Not Available
Internal haemorrhage24.07.01.0720.000742%Not Available
The 9th Page    First    Pre   9    Total 9 Pages